AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12057615 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dose schedule (0 and 6 months) using Twinrix paediatric (360 EL.U HAV antigen/10 microg HBs antigen)
Number of subjects: 100
Study 12057615 — intervention group
Group type: COMPARATOR
Intervention: Three dose schedule (0, 1 and 6 months) using adult formulation (720 EL.U HAV antigen/20 microg HBs antigen)
Number of subjects: 100
Study 7916546 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SST) administered intrathecally and epidurally, mean daily dose 1,252 μg (range 250-3,000 μg), mean duration 11.3 days
Number of subjects: 8
Study 7916546 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SST)
Number of subjects: 8
Study 2589241 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 120
Study 179223 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with Adriamycin
Number of subjects: 0
Study 179223 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneously given polychemotherapy
Number of subjects: 0
Study 179223 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy
Number of subjects: 0
Study 31472154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural manometry
Number of subjects: 70
Study 31472154 — intervention group
Group type: COMPARATOR
Intervention: Normal PEL
Number of subjects: 70
Study 31472154 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-drainage chest radiograph
Number of subjects: 70
Study 31472154 — intervention group
Group type: COMPARATOR
Intervention: Post-thoracentesis chest radiograph
Number of subjects: 70
Study 31472154 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance between post-procedural chest radiograph and pleural manometry results
Number of subjects: 70
Study 27979753 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2 intervention arm CCCs receive implementation of a daily curricula for teachers/parents, children, snack, beverage, physical activity, and screen time policies, and technical assistance with menu modifications.
Number of subjects: 24
Study 27979753 — intervention group
Group type: COMPARATOR
Intervention: Attention control safety curriculum
Number of subjects: 24
Study 26743856 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice a day
Number of subjects: 703
Study 26743856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 26743856 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice a day (in patients with EGFR mutations)
Number of subjects: 703
Study 26743856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with EGFR mutations)
Number of subjects: 703
Study 23493968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with asthma
Number of subjects: 285
Study 23493968 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without asthma
Number of subjects: 285
Study 23493968 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed viral infection in women with asthma
Number of subjects: 285
Study 21623001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic humeral centering (DHC)
Number of subjects: 69
Study 21623001 — intervention group
Group type: COMPARATOR
Intervention: Non-specific mobilisation (control)
Number of subjects: 69
Study 19651013 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hong Kong procedure without instrumentation (Group A)
Number of subjects: 62
Study 19651013 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hong Kong procedure with additional instrumentation (Group B)
Number of subjects: 62
Study 19651013 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 62
Study 16424116 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber supplement (3 g/d)
Number of subjects: 29
Study 16424116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15098638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consult clinic
Number of subjects: 126
Study 11089824 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling (15 home-based counselling visits, including two visits in the last trimester and three early postpartum visits)
Number of subjects: 726
Study 11089824 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling
Number of subjects: 726
Study 11089824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer counselling)
Number of subjects: 726
Study 9624542 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose fosfomycin trometamol
Number of subjects: 547
Study 9624542 — intervention group
Group type: COMPARATOR
Intervention: 5-day course of trimethoprim
Number of subjects: 547
Study 9624542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 547
Study 7836192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Training (IT)
Number of subjects: 0
Study 7836192 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Training (MT)
Number of subjects: 0
Study 7836192 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Trioxsalen bath-PUVA treatment (0.2 mg/L solution)
Number of subjects: 0
Study 2968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen bath-PUVA treatment (0.4 mg/L solution)
Number of subjects: 0
Study 2968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen bath-PUVA treatment with UVA doses similar to trioxsalen
Number of subjects: 0
Study 2968374 — intervention group
Group type: COMPARATOR
Intervention: Trioxsalen bath-PUVA treatment (control for methoxsalen)
Number of subjects: 0
Study 29843525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation plus inspiratory muscle training (PR + IMT group)
Number of subjects: 34
Study 29843525 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation group (PR group)
Number of subjects: 34
Study 29843525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 28477440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous fluocinolone acetonide implant
Number of subjects: 215
Study 28477440 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids and immunosuppression
Number of subjects: 215
Study 23020135 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal zinc supplementation
Number of subjects: 259
Study 23020135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 259
Study 23908551 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 4% spray gel
Number of subjects: 232
Study 23908551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 232
Study 21284481 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks)
Number of subjects: 23
Study 21284481 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 23
Study 21284481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18035519 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential cognitive therapy (RCT)
Number of subjects: 80
Study 18035519 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential interpersonal therapy (RIPT)
Number of subjects: 80
Study 18035519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RCT and RIPT
Number of subjects: 80
Study 16425182 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 microg/m(2) GM-CSF subcutaneously three times a week until clinical progression
Number of subjects: 0
Study 16425182 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg/m(2) GM-CSF subcutaneously three times a week until clinical progression
Number of subjects: 0
Study 12692706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 12
Study 12692706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 43
Study 10843245 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 43
Study 10843245 — intervention group
Group type: COMPARATOR
Intervention: Non-dialyzed ESKD patients
Number of subjects: 43
Study 10843245 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 9337505 — intervention group
Group type: EXPERIMENTAL
Intervention: JOBS II intervention
Number of subjects: 0
Study 9337505 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation against setbacks (part of JOBS II intervention)
Number of subjects: 0
Study 9337505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7899626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intra- and extra-articular plasty (iliotibial band tenodesis)
Number of subjects: 32
Study 7899626 — intervention group
Group type: COMPARATOR
Intervention: Isolated intra-articular semitendinosus reconstruction
Number of subjects: 32
Study 3314645 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg phenoxybenzamine orally
Number of subjects: 60
Study 3314645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29573055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-matched pRBCs
Number of subjects: 48
Study 29573055 — intervention group
Group type: COMPARATOR
Intervention: Noncross-matched pRBCs
Number of subjects: 48
Study 25728984 — intervention group
Group type: EXPERIMENTAL
Intervention: IA cisplatin 150 mg/m²
Number of subjects: 237
Study 25728984 — intervention group
Group type: COMPARATOR
Intervention: IV cisplatin 100 mg/m²
Number of subjects: 237
Study 24272830 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating and ranking values clarification method
Number of subjects: 920
Study 24272830 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance sheet values clarification method
Number of subjects: 920
Study 24272830 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete choice experiment (DCE) values clarification method
Number of subjects: 920
Study 24272830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT)
Number of subjects: 920
Study 24272830 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 920
Study 23773895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 54
Study 23773895 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation care
Number of subjects: 54
Study 19913821 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 33
Study 19999230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide free group
Number of subjects: 200
Study 19999230 — intervention group
Group type: COMPARATOR
Intervention: N2O group
Number of subjects: 200
Study 16627439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 94
Study 16627439 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 94
Study 16627439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 14616255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of 17beta‐estradiol plus 0.5 mg of norethisterone acetate
Number of subjects: 44
Study 14616255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 44
Study 10771224 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRS implantation (Intacs) in bilateral treatment group
Number of subjects: 134
Study 10771224 — intervention group
Group type: COMPARATOR
Intervention: ICRS implantation (Intacs) in unilateral treatment group
Number of subjects: 134
Study 9190245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrosol
Number of subjects: 70
Study 9190245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1568575 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg per hour)
Number of subjects: 10
Study 1568575 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 10
Study 3911362 — intervention group
Group type: EXPERIMENTAL
Intervention: diethyl‐carbamazine
Number of subjects: 0
Study 3911362 — intervention group
Group type: COMPARATOR
Intervention: ivermectin
Number of subjects: 0
Study 29925494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tailored story intervention
Number of subjects: 792
Study 29925494 — intervention group
Group type: COMPARATOR
Intervention: Low-tailored story intervention
Number of subjects: 792
Study 29925494 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes smoked per day
Number of subjects: 792
Study 29925494 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 792
Study 27043681 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (once-daily) from admission day until discharge
Number of subjects: 42
Study 27043681 — intervention group
Group type: COMPARATOR
Intervention: No atorvastatin treatment until discharge, atorvastatin started after discharge
Number of subjects: 42
Study 25293900 — intervention group
Group type: EXPERIMENTAL
Intervention: First aid training course
Number of subjects: 500
Study 23045348 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A injection into the soleus muscle
Number of subjects: 14
Study 20466293 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genetic counseling (experimental group)
Number of subjects: 193
Study 20466293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no comprehensive genetic counseling)
Number of subjects: 193
Study 20466293 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression levels (both groups)
Number of subjects: 193
Study 18712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric multiple imputation method for competing risks failure times
Number of subjects: 0
Study 18712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier imputation method for censoring times
Number of subjects: 0
Study 16722852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tielle hydropolymer dressings
Number of subjects: 6993
Study 12848776 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg DEX hydro-bromide
Number of subjects: 22
Study 12848776 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg DEX hydro-bromide
Number of subjects: 22
Study 12848776 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg DEX hydro-bromide preceded at 1 h by quinidine HCl (50 mg)
Number of subjects: 22
Study 12848776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10098822 — intervention group
Group type: EXPERIMENTAL
Intervention: Harassment
Number of subjects: 60
Study 10098822 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 8906205 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (G-2)
Number of subjects: 0
Study 8906205 — intervention group
Group type: COMPARATOR
Intervention: Control (G-1)
Number of subjects: 0
Study 1797506 — intervention group
Group type: COMPARATOR
Intervention: 125I‐labeled human soluble insulin (Actrapid HM U‐100)
Number of subjects: 7
Study 1797506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeric analogue AspB10
Number of subjects: 7
Study 1797506 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogue AspB28
Number of subjects: 7
Study 1797506 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomeric analogue AspB9, GluB27
Number of subjects: 7
Study 1797506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexameric human insulin
Number of subjects: 7
Study 6817370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline
Number of subjects: 0
Study 6817370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pargyline
Number of subjects: 0
Study 31889500 — intervention group
Group type: EXPERIMENTAL
Intervention: Myositis patients
Number of subjects: 108
Study 31889500 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 108
Study 31889500 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 108
Study 27896952 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 255
Study 27896952 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 255
Study 27896952 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 255
Study 27499448 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg DHA per day
Number of subjects: 197
Study 27499448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 27499448 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal supplementation with 600mg/d DHA
Number of subjects: 197
Study 24918788 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 21659848 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% pirfenidone (PFD) gel administered topically 3 times a day during 6 months
Number of subjects: 33
Study 21659848 — intervention group
Group type: COMPARATOR
Intervention: Pressure therapy
Number of subjects: 33
Study 19010549 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment (better eye <6/18) after best correction
Number of subjects: 1375
Study 19010549 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindness (better eye <3/60) after best correction
Number of subjects: 1375
Study 17447977 — intervention group
Group type: EXPERIMENTAL
Intervention: NB-UVB
Number of subjects: 50
Study 17447977 — intervention group
Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 50
Study 15246726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transfer of autologous bone‐marrow cells
Number of subjects: 60
Study 15246726 — intervention group
Group type: COMPARATOR
Intervention: Optimum postinfarction medical treatment (Control)
Number of subjects: 60
Study 12042287 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound scan by a single ultrasonographer
Number of subjects: 27
Study 9891896 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 23
Study 9891896 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 23
Study 7698046 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD peptide matrix (Argidene Gel) applied topically twice weekly for up to 10 weeks
Number of subjects: 65
Study 7698046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topical saline) plus standard care
Number of subjects: 65
Study 7698046 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD peptide matrix
Number of subjects: 65
Study 2260915 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol or its conjugate
Number of subjects: 8
Study 2260915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol
Number of subjects: 8
Study 2260915 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens (general)
Number of subjects: 8
Study 25030 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted diazepam
Number of subjects: 0
Study 25030 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted diazepam (10 mg diluted to 20-40 ml)
Number of subjects: 0
Study 25030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (undiluted or diluted)
Number of subjects: 0
Study 31776027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 601
Study 31776027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 31263553 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified training curriculum and pictorial tools for RECOs
Number of subjects: 152
Study 31263553 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard tools and training)
Number of subjects: 152
Study 27699618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary implementation strategy
Number of subjects: 128
Study 27699618 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions
Number of subjects: 128
Study 27699618 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 128
Study 26444157 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna Boot
Number of subjects: 18
Study 26444157 — intervention group
Group type: COMPARATOR
Intervention: Elastic bandage
Number of subjects: 18
Study 22959478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (16 mg oral dose)
Number of subjects: 6
Study 22959478 — intervention group
Group type: COMPARATOR
Intervention: Control (no rapamycin)
Number of subjects: 6
Study 21752315 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX) treatment at 30-40 mg/kg•d
Number of subjects: 24
Study 21752315 — intervention group
Group type: COMPARATOR
Intervention: Control group (deferoxamine and deferiprone)
Number of subjects: 24
Study 20145794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealer
Number of subjects: 69
Study 20145794 — intervention group
Group type: COMPARATOR
Intervention: Standard electrocautery
Number of subjects: 69
Study 17437788 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m² on days 1 and 8 plus 70 mg/m² cisplatin or carboplatin (AUC 5) on day 1, repeated every 21 days for 6 cycles
Number of subjects: 23
Study 16342089 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 375 mg twice a day
Number of subjects: 672
Study 16342089 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg twice a day
Number of subjects: 672
Study 16342089 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 125 mg twice a day
Number of subjects: 672
Study 16342089 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg once a day
Number of subjects: 672
Study 16342089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 16342089 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice a day
Number of subjects: 672
Study 12475455 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty with stenting (PCI)
Number of subjects: 102
Study 12475455 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (surgery)
Number of subjects: 102
Study 9619746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU + IFNalpha-2a
Number of subjects: 205